Category Archives: Stem Cell Doctors


Lies and Hypocrisy: Anti-Abortion Arguments to Restrict the Abortion Pill – Ms. Magazine

The anti-abortion movement is pressing the Trump administration to rescind changes and even more severely tighten restrictions on the abortion pill. (support circle / Flickr)

The anti-abortion movement has fought a long-standing battle against access to the abortion pill. In the 1980s, they threatened to boycott drug companies developing the drug. In the 1990s, they waged a campaign to block FDA approval of the pill; although finally approved in late 2000, severe restrictions were placed on distribution of the pill by the FDA.

After research showed that a lower dosage of 200 mginstead of 600 mgwas just as effective and caused fewer side effects, and that the drug could be used safely later into pregnancyuntil 70 days instead of 49anti-abortion advocates pressured the FDA for years to maintain the higher dosage and shorter timeline for usage of the pill.

Under the Obama administration, the FDA finally approved the lower dosage and longer timeline in 2016, but today the anti-abortion movement is pressing the Trump administration to rescind those changes and even more severely tighten restrictions on the abortion pill.

Through these campaigns to suppress theusage of the abortion pill, anti-abortion advocates have spread misleading and false information about the safety and efficacy of the abortion pill.

A glaring contemporary example of this strategy is the right-wing Family Research Council (FRC)s recent report, titled The Next Abortion Battleground: Chemical Abortion.

Founded in 1983 as a division of James Dobsons religious right organization Focus on the Family, the Family Research Council is now one of the far rights most powerful advocacy groups, fighting against abortion, stem cell research and LGBTQ equality, and promoting the Judeo-Christian worldview as the basis for a just, free and stable society.

The FRCs chemical abortion report is full of lies and misrepresentations, citing discredited research and junk science. The report uses inflammatory and misleading language, and is replete with hypocritical arguments.

One way FRC tries to mislead the public is by using inflammatory and alarmist language.

For example, they use the phrase chemical abortion to make abortion pills sound dangerouswhen in fact they are very safe.

Here atMs., our team is continuing to report throughthis global health crisisdoing what we can to keep you informed andup-to-date on some of the most underreported issues of thispandemic.Weask that you consider supporting our work to bring you substantive, uniquereportingwe cant do it without you. Support our independent reporting and truth-telling for as little as $5 per month.

Throughout the report, they refer to embryos and fetuses as babies, and they describe misoprostol as a drug that yanks the baby out of the womb. They refer to medication abortion as a violent regimen. Their language is misleading and overwrought.

The FRC report repeatedly refers to the abortion industryan attempt to make doctors and other clinicians providing abortion health care sound nefarious and exploitative.

This extreme and inflammatory language demonizes people providing and having abortions. But FRC goes farther. They explicitly lie about the risks of medication abortion.

The FRC report is riddled with misrepresentations and outright lies about the safety of medication abortion. They claim that the abortion pill poses profound dangers to women. In fact, mifepristone is an extremely safe drug.

The FRC plucks from the mifepristone medication guide the rarest but most severe drug reactions and frames them as common. FRC cites discredited research and junk science, making the false claim that abortion causes depression, and then claims, without evidence, that medication abortion is uniquely traumatic to women, more so than aspiration abortion.

FRC inaccurately claims that mifepristone is subject to the FDAs drug safety programRisk Evaluation and Mitigation Strategies (REMS)because it carries such life-threatening risks. In fact, mifepristone is subject to the REMS restriction because of politics, not safety concerns. Mifepristone issix times safer than Viagrawhich the FDA does not restrict under the REMS program.

The REMS restriction means that mifepristone cannot be distributed through pharmacies like most other drugs. Instead, only doctors registered with the manufacturer can dispense the pill to their patients.

Throughout the report, the FRC inaccurately argues that removing the FDA REMS restriction would lead to the abortion pill being available over the counter, making do-it-yourself abortions the norm. In fact, in the absence of the REMS restriction, the abortion pill would be treated like most other drugsavailable at pharmacies by prescription, under the supervision of a doctor. Simply removing the FDA REMS restriction would not result in do-it-yourself abortion.

At the end of their report, the FRC calls on the FDA to strengthen restrictions on the abortion pill, prohibit telemedicine abortion and require doctors to conduct unnecessary physical examinations of patients receiving the abortion pill. These barriers would significantly decrease access to medication abortion and increase the costs.

FRC also calls for the criminal prosecution of Rebecca Gomperts of AID Access, who assists people in obtaining and using the abortion pill, as well as cracking down on online pharmacies that sell the pill.

Finally, they call for shutting down Gynuity Health Projects TelAbortion study, which allows an exception to the REMS restriction in certain states.

In fact, they are terrified of the power and control that the abortion pill puts into womens hands. They hate the way that medication abortion can avoid the obstacles and restrictions they have constructed over the last 47 years since Roe v. Wade legalized abortion in the United States.

A cheap, widely accessible abortion pill that women could obtain through the mail and take in the privacy of their own homes would mean anti-abortion extremists would lose the opportunity to harass and yell at women going into and out of clinics, terrorizing them with their abuse.

The National Womens Health Network is leading a campaign to raise awareness about the FDA restrictions on the abortion pill, pressure the FDA to lift the restrictions, and make the abortion pill more widely available. You can find resources for the campaign on their website, which they encourage people to share widely using the hashtag #MailTheAbortionPill.

Public policy must be based on medical science and genuine concern for womens healthnot on the lies, misrepresentations and hypocrisy of hate groups like the Family Research Council.

The coronavirus pandemic and the response by federal, state and local authorities is fast-moving.During this time,Ms. is keeping a focus on aspects of the crisisespecially as it impacts women and their familiesoften not reported by mainstream media.If you found this article helpful,please consider supporting our independent reporting and truth-telling for as little as $5 per month.

See the original post here:
Lies and Hypocrisy: Anti-Abortion Arguments to Restrict the Abortion Pill - Ms. Magazine

Here Are a Bunch of Photos of Cops Not Wearing Masks – Futurism

At a protest in Queens, I asked a police officer why he wasnt wearing a mask.

Coronas over, he replied.

As Black Lives Matter protests against police violence and systematic racism erupted across the country, an unfortunate trend has emerged: while police often show up heavily armed and wearing riot gear, they seldom wear medical masks or other face coverings to prevent COVID-19 from spreading.

By not wearing masks, police are putting themselves and others at a greater risk of catching the coronavirus, experts told Time.

If a state, if a county, if a city is telling the general public to wear masks, Johns Hopkins health researcher Amesh Adalja told Time, then the police officers must follow that same law.

While a number of public health experts have argued that protestors are unlikely to cause a huge explosion in coronavirus infections, that assumes that everyone takes basic common-sense measures like keeping distance where possible and wearing a medical mask that keeps them from spreading pathogens.

Some cops are skipping masks entirely. Others are wearing them wrong, by pulling them down to expose their noses or mouths.

And while being outdoors likely reduces the risk of transmission, tightly clustered police and the protestors they arrest become public health hazards. Meanwhile, as of May 4, the NYPD had spent $12 million on medical masks this year alone, pointing to a major waste of time and resources given how few cops actually wore them.

I attended multiple protests and vigils throughout New York City. At all of them, the majority of police opted to skip the face mask or wear it improperly.

Videos from other protests, like this one of Austin police opening fire on a crowd of peaceful protestors, highlight that the problem of police ignoring their masks is a national issue.

Read more:
Here Are a Bunch of Photos of Cops Not Wearing Masks - Futurism

Cryo-Cell to Donate 50,000 Face Masks to OBGYN Practices and Patients Around the Country Amidst COVID-19 – PR Web

We recognize and salute the vital role that physicians and other healthcare providers play in taking care of pregnant women, especially during the COVID-19 pandemic.

OLDSMAR, Fla. (PRWEB) June 08, 2020

Cryo-Cell Internationals announcement comes on the heel of increased demand for masks and other protective measures to protect workers in the medical field. The face masks will be distributed nationwide to obstetrical and gynecological doctors and their dedicated staffs who valiantly risk their lives every day to provide healthcare to pregnant women. The delivery of masks is scheduled to begin later this week.

In addition to face mask donations, Cryo-Cell International has and will contribute other essential supplies within the medical field including face shields, hand sanitizers, and informational pieces regarding COVID-19 for practitioners and pregnant patients alike.

David Portnoy, Cryo-Cell Internationals Chairman and Co-CEO, stated, We recognize and salute the vital role that physicians and other healthcare providers play in taking care of pregnant women, especially during the COVID-19 pandemic. In support of their noble efforts, Cryo-Cell International is proud to provide essential medical items to allow them to provide the highest quality care for their patients.

Cryo-Cell International remains committed to providing clients with premier cord blood and cord tissue preservation service and aiding in the advancement of regenerative medicine. As research continues to develop in finding treatments for COVID-19 through the use of mesenchymal stem cells found in cord tissue, the company continues to help expecting parents protect what matters most through umbilical stem cell preservation. Cryo-Cell International anticipates ongoing plans to aid in financial contributions and personal protective equipment donations to help safeguard the efforts of essential workers in OBGYN practices around the United States during COVID-19.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant, and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly-traded company, OTCQB:CCEL. For more information, please visit http://www.cryo-cell.com. For a complete list of references, visit http://www.cryo-cell.com/references.

Forward-Looking Statement Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company, which include future medical and research developments. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

Share article on social media or email:

More:
Cryo-Cell to Donate 50,000 Face Masks to OBGYN Practices and Patients Around the Country Amidst COVID-19 - PR Web

Coronavirus: Abu Dhabi invests Dh3.6m in new technology to boost Covid-19 fight – The National

Pioneering scientists in Abu Dhabi have unveiled new cutting-edge technology which is set to provide vital support to patients battling Covid-19.

The Abu Dhabi Stem Cell Centre (ADSCC) has invested Dh3.6 million on a Helios Mass Cytometer, a state-of-the-art tool which experts say will help bolster the bodys defence against the virus.

The cytometer, the only one of its kind in the Middle East, will enable scientists at the centre to quickly and accurately profile individual human cells, allowing them to study and monitor a patients immune response to the virus.

"With this tool, the ADSCC can study clinical outcomes and changes in inflammatory or immune function from blood samples of Covid-19 patients, an ADSCC spokesperson said.

"This will allow us to address some of the pressing questions that remain unanswered regarding Covid-19.

Staff at the centre are currently receiving training on the operation of the new machine, which they have affectionately dubbed ''The Lamborghini''.

Scientists leading efforts to stem the spread of Covid-19 are seeking to assess whether those most at risk of severe symptoms can be identified early, what interventions can reduce its severity and what vaccines will prove most effective in staving off the virus.

The centre recently introduced a new therapy to treat the effects of Covid-19, which has proved fruitful for a number of patients with severe symptoms.

It involves isolating then activating stem cells taken from the patient's blood before they are nebulised into a fine mist so they can be inhaled into the lungs.

The first UAE patient to recover from Covid-19 after undergoing the stem-cell therapy told The National last month of his gruelling journey to "full health" after being placed in a coma to stop his organs shutting down.

Members of a Palestinian team called ''Bella Ciao", dressed as actors of "La Casa de Papel (Money Heist)" series, perform in Gaza City. Reuters

A man takes a selfie with a member of ''Bella Ciao". Reuters

Iraqi medical specialists take part in a testing process for the coronavirus in Baghdad's Karada district. EPA

Iraqi medical specialists take a blood sample from a man for a coronavirus test in Baghdad's Karada district. EPA

Customers sit at a cafe in Damascus, Syria. EPA

Customers sit on the terrace of a cafe in Damascus, Syria. EPA

Iranians walk past in a street, in Tehran. EPA

A Muslim performs the Friday prayers inside the Al-Rajhi Mosque, Riyadh, Saudi Arabia. Reuters

Muslims perform the Friday prayers inside the Al-Rajhi Mosque, Riyadh, Saudi Arabia. Reuters

Yemenis walk past historic buildings in the old quarter of Sanaa. EPA

A worker disinfects a shopper's hands before they enter a mall in Sanaa, Yemen. AP Photo

Jordanians perform their first Friday prayers since the start of the pandemic at a mosque in Amman. EPA

Believers gather in a mosque in Tunis. Tunisia. AP Photo

A drone with a thermal camera flies over Habib Burgiba Street in Tunis, Tunisia. EPA

Mohamed Hawas Al Sadid, CEO of Ambulatory Healthcare Services, at the the new Covid-19 Prime Assessment Centre at ADNEC, Abu Dhabi. Victor Besa

Covid-19 positive residents in the waiting room at the new Prime Assessment Center at ADNEC, Abu Dhabi. Victor Besa

Abdullahi Rodhile, 50, from Somalia, contracted the virus on March 30 and, because of an existing heart condition, his health deteriorated quickly.

The virus attacked his kidneys and lungs so badly that doctors rushed him into the intensive care unit at Sheikh Khalifa Medical City in Abu Dhabi and put him in an induced coma for 20 days.

I was brought back to life. I was dead and now I am alive, said Mr Rodhile, who works as a cargo clerk.

I have never been better. Thank God."

He spent 40 days in intensive care but only after he started the stem cell therapy did his lungs begin to improve slightly.

Mr Rodhile eventually healed enough to gradually awaken from the coma.

Scientists at Abu Dhabi Stem Cell Centre are continuing to harness latest technologies in order to aid patients in ill health.

The centre announced on Saturday it is to begin offering Minimal Residual Disease tests for cancer patients a first in the UAE.

The highly specialised test allows physicians to spot residual, potentially-resistant cells that can lead to a relapse in patients. Currently such a test is not available in the Emirates and cancer patients have to travel abroad to be tested because the test requires the use of a fresh sample to be accurate.

Updated: June 6, 2020 02:26 PM

Originally posted here:
Coronavirus: Abu Dhabi invests Dh3.6m in new technology to boost Covid-19 fight - The National

Bald men at higher risk of having severe coronavirus, shocking new research suggests – Express

Researchers believe the link is so strong that they have called for baldness to be listed as a risk factor called the Gabrin sign This is after Dr Frank Gabrin, the first US physician to die of coronavirus, who was also bald. Lead author of the study, Professor Carlos Wambier of Brown University, told The Telegraph: "We really think that baldness is a perfect predictor of severity."

Recently scientists have hypothesised that coronavirus is more deadlier for men due than women because of testosterone.

Italian doctors have previously found patients given androgen deprivation therapy, which radically cuts testosterone levels, were four times less likely to die from coronavirus.

A protein, TMPRSS2, is driven up by testosterone and scientists think the virus could use this protein to help it unlock cells.

Researchers at Londons Institute for Cancer Research are examining the link further, whilst the University of California, Los Angeles is looking at testosterone-blocking therapy to help with coronavirus treatment.

Testosterone can produce dihydrotestosterone (DHT) which can lead to hair loss.

Though as per South China Morning Post, it is possible to have low levels of testosterone but high levels of DHT.

The further data on baldness further raises the possibility that treatments that cut testosterone could be used to slow the virus down.

Discussions have taken place about a trial using baldness drugs to treat coronavirus.

READ MORE:Chinas Xi Jinping vows to strengthen public health system

A study of 122 patients in three Madrid hospitals found 79 percent of the men were bald.

Howard Soule, executive vice president at the Prostate Cancer Foundation, told Science Magazine: "Everybody is chasing a link between androgens and the outcome of Covid-19.

Karen Stalbow, Head of Policy at Prostate Cancer UK, said: There have been several recent pieces of research which indicate there may be a link between male hormones and increased risk of Covid-19.

This has led some researchers to investigate whether hormone therapies commonly used to treat prostate cancer, such as enzalutamide, could reduce this risk.

DON'T MISS

New Yorks coronavirus came from Europe and NOT China (LATEST)Antimalarial drug study withdrawn as authors deny its authenticity (ANALYSIS)Vaccine summit in UK exceeds target by raising nearly 7 billion(NEWS)

However, most of the research so far has been in the lab, and there is conflicting evidence over whether the hormone therapies have the same impact in the lungs as they would in prostate cells.

There are now several clinical studies starting which hope to address these issues, but much more evidence is needed before we can know whether these hormone therapies would be an effective treatment for Covid-19.

Professor Nick James of the Institute for Cancer Research has warned against using testosterone cutting treatment as a preventive measure due to their severe side effects.

He explained to the Mail on Sunday: Being on these drugs is the male equivalent of going through the menopause.

You would almost certainly cause more harm than good.

According to the NHS, the following people are considered clinically extremely vulnerable: people who have had an organ transplant, people undergoing chemotherapy or antibody treatment for cancer, intense radiotherapy, cancer treatments which affect the immune system, people who have blood or bone marrow cancer, those have had a bone marrow or stem cell transplant in the previous six months, or are still taking immunosuppressant medicine, those with a severe lung condition, those with a condition which puts them at high risk of infection or taking medicines which makes them more likely to do so and expecting mothers with heart conditions.

The list of people are considered at moderate risk includes: Those over 70, expecting mothers, those who have lung conditions which are not severe, those with heart disease, diabetics, those with chronic kidney disease, those with liver disease, those with a condition affecting the brain or nerves and those who are obese.

Previously, environmental factors were hypothesised as being behind the higher risk to men.

This includes the fact men are more likely to be smokers.

Read more from the original source:
Bald men at higher risk of having severe coronavirus, shocking new research suggests - Express

Cells inside Cells: The Bacteria That Live in Cancer Cells – ETHealthworld.com

In a research conducted by Dr. Ravid Straussman's supported by the Roel C. Buck Career Development Chair and the European Research Council.

Dr. Ravid Straussman stated that cancer cells are comfy havens for bacteria. The conclusion arise from a rigorous study of over 1,000 tumor samples of different human cancers. The study, headed by researchers at the Weizmann Institute of Science, found bacteria living inside the cells of all the cancer types from brain to bone to breast cancer and even identified unique populations of bacteria residing in each type of cancer. The research suggests that understanding the relationship between a cancer cell and its mini-microbiome may help predict the potential effectiveness of certain treatments or may point, in the future, to ways of manipulating those bacteria to enhance the actions of anticancer treatments. The findings of this study were published in Science.

Dr. Ravid Straussman of the Institutes Molecular Cell Biology Department had, several years ago, discovered bacteria lurking within human pancreatic tumor cells; these bacteria were shown to protect cancer cells from chemotherapy drugs by digesting and inactivating these drugs. When other studies also found bacteria in tumor cells, Straussman and his team wondered whether such hosting might be the rule, rather than the exception. To find out, Drs. Deborah Nejman and Ilana Livyatan in Straussmans group and Dr. Garold Fuks of the Physics of Complex Systems Department worked together with a team of oncologists and researchers around the world. The work was also led by Dr. Noam Shental of the Mathematics and Computer Science Department of the Open University of Israel.

Ultimately, the team would produce a detailed study describing, in high resolution, the bacteria living in these cancers brain, bone, breast, lung, ovary, pancreas, colorectal and melanoma. They discovered that every single cancer type, from brain to bone, harbored bacteria and that different cancer types harbor different bacteria species. It was the breast cancers, however, that had the largest number and diversity of bacteria. The team demonstrated that many more bacteria can be found in breast tumors compared to the normal breast tissue surrounding these tumors, and that some bacteria were preferentially found in the tumor tissue rather than in the normal tissue surrounding it.

The team also reported that bacteria can be found not only in cancer cells, but also in immune cells that reside inside tumors. Some of these bacteria could be enhancing the anticancer immune response, while others could be suppressing it a finding that may be especially relevant to understanding the effectiveness of certain immunotherapies, says Straussman. Indeed, when the team compared the bacteria from groups of melanoma samples, they found that different bacteria were enriched in those melanoma tumors that responded to immunotherapy as compared to those that had a poor response.

Straussman thinks that the study can also begin to explain why some bacteria like cancer cells and why each cancer has its own typical microbiome: The differences apparently come down to the choice of amenities offered in each kind of tumor-cell environment. That is, the bacteria may live off certain metabolites that are overproduced by or stored within the specific tumor types. For example, when the team compared the bacteria found in lung tumors from smokers with those from patients who had never smoked, they found variances. These differences stood out more clearly when the researchers compared the genes of these two groups of bacteria: Those from the smokers lung cancer cells had many more genes for metabolizing nicotine, toluene, phenol and other chemicals that are found in cigarette smoke.

In addition to showing that some of the most common cancers shelter unique populations of bacteria within their cells, the researchers believe that the methods they have developed to identify signature microbiomes with each cancer type can now be used to answer some crucial questions about the roles these bacteria play: Are the bacteria freeloaders on the cancer cells surplus metabolites, or do they provide a service to the cell? At what stage do they take up residence? How do they promote or hinder the cancers growth? What are the effects that they have on response to a wide variety of anticancer treatments?

Tumors are complex ecosystems that are known to contain, in addition to cancer cells, immune cells, stromal cells, blood vessels, nerves, and many more components, all part of what we refer to as the tumor microenvironment. Our studies, as well as studies by other labs, clearly demonstrate that bacteria are also an integral part of the tumor microenvironment. We hope that by finding out how exactly they fit into the general tumor ecology, we can figure out novel ways of treating cancer, Straussman says.

See the rest here:
Cells inside Cells: The Bacteria That Live in Cancer Cells - ETHealthworld.com

Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. – ETHealthworld.com

By Smridhi Uppal

In an interaction with EThealthworld, Mr. Chetan Makam, Managing Director, Terumo Penpol Pvt. Ltd talks about how Covid19 has affected the essentials industry in carrying out new normals with respect to terms of supply and demand.

How has the covid-19 pandemic impacted the healthcare sector?The healthcare sector has various segments; delivery of patient care, medical devices, pharma etc. and each of them has been affected in different ways.

TerumoBCT specializes in the manufacturing of medical equipment, particularly equipments used in blood and cell collections. The need for blood never diminishes as patients need blood and blood components for a variety of treatments such as oncology, sickle cell disease, maternal and child health related intervention and for emergency surgeries.

In India, ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them.

What are the major investments that TerumoBCT is continuing to make?

We at Terumo Penpol conduct a couple of hundred blood donation drives and promote voluntary blood donation (VBD). Our CSR activities include support for various organizations working in Thalassemia, Hemophilia as well as in stem cell donations.

Terumo is an established company in Kerala. We continue to invest both in the well-being of our associates and in high quality medical devices that support the demands of the local market and in fact, the world. The reliability of the local supply chain, products from our facility make their way around the globe to meet essential healthcare needs.

Terumo Penpol was the first medtech company chosen to participate in the Japan-India Institute of Manufacturing (JIM) program. Overseen by the Japanese Ministry of Economy, Trade and Industry, JIM was borne out of PM Narendra Modis request to his Japanese counterpart Shinzo Abe for support to scale up industrial work skills among Indian youth. Our participation contributes to the Skill India, Make in India and Ayushman Bharat initiatives.

We have invested over the past few years in a comprehensive and established Business Continuity Policy, designed to safeguard associates around the world and ability to deliver products worldwide. Guided by this policy and social responsibility to healthcare, we are committed to providing continuous support to customers so they can continue their business operations during critical events as they rely on the quality of products and the services we provide.

How has your company contributed to combating this pandemic?We continue to operate our factories and provide products and services to our customers globally as they depend on us to collect blood, cells and now plasma, while ensuring that our employees are working in safe conditions.Our parent company, Terumo Corporation, has donated USD 2.4 million in cash and products to support COVID-19 relief efforts worldwide including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO. The Solidarity Response Fund supports research and development of new therapies and vaccines, global response to the pandemic, such as tests and personal protective equipment, and education and communication efforts to protect individuals against the infection.

Terumo BCT specifically, focused on unlocking the potential of blood and cells and to the contributing solutions that can have an impact now to fight against COVID-19. In the current context, our products are uniquely placed to cater to various medical interventions. We have a product for convalescent plasma collection, which provides passive immunity to patients with COVID-19 and may help preventing infection in high risk groups, such as healthcare workers. Our Pathogen Reduction Technology system is already being used in many countries to add a layer of safety in blood transfusion and recently for convalescent plasma.

Similarly, we have also a product to help treat respiratory failure in adult patients with confirmed COVID-19. The treatment reduces pro-inflammatory cytokine levels, which cause cytokine storm. The cytokine storm that occurs in some COVID-19 patients, leads to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

What are your expectations from the government?The local government in Thiruvananthapuram, Kerala has provided us with the permissions to operate as an essential industry. Given the treatments and technologies that we can bring to serve more patients, having a process with the regulators to provide emergency use authorization would be a plus. Expedited approvals for products made at multiple locations to ensure business continuity. Relief on import duties on products for the duration of the COVID restrictions to offset the cost of increased freight. Governments can also help by paying outstanding dues immediately.

How do you think this crisis will affect the balance sheets of firms?The key for many companies will be to devise ways to conserve cash as it will allow them to be flexible and respond better to the changing scenarios. its the time to reduce 1 percent from the CSR activities and conserve money for investing tomorrow, by authorizing 2 percent from it.

What are the challenges do you see in Make in India? I am glad to see that the Government of India is bringing in policies to make India a manufacturing hub for medical devices. What is encouraging is that the government is emphasizing on the need for the products to be at par with international standards so that it can cater to the domestic as well as overseas markets. This is indeed a progressive outlook and need to be applauded. One area which needs to be addressed is absence of skilled labour to support domestic/local manufacturing of medical devices.

Hence skilling of labour force is necessary. Another area where there has been a lacuna in most cases is absence of collaborative approach wherein government, private sector and academia join forces for better outcome. However, in the fight against COVID- 19, Indias mitigation response has seen collaborative research and innovation.

Indian Government, academia, and the private sector have come together to bring in pioneering solution. Following this triple helix approach even in the long-term (post-COVID) would benefit the medical device players as well as the customers as it brings together capabilities and resources to solve common problems more efficiently. For the government, it helps address healthcare challenges through innovative and cost-effective approaches.

ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them. Hence, it is important to take forward this very important learning from the pandemic and MNCs and local manufacturers should work in tandem to bring in effective solutions to address healthcare challenges in India and globally.

Tell us something about the latest developments and global trends in medical devices associated with blood industry? Spectra Optia apheresis system has seen interesting developments recently. In Covid-19 patients, it aims reduce the number of cytokines and other inflammatory blood proteins that control a cells immune response, filtering the blood and returning it to the patient. The proteins that are removed are typically elevated during infections and can be associated with a cytokine storm that occurs in some COVID-19 patients, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

Another interesting development has been that researchers have established that exposing the novel coronavirus to the vitamin riboflavin and ultraviolet light decreases the viral count in human plasma and whole-blood products, a development that may help lower the possibility of transmission of the virus via blood transfusion. The scientists from Colorado State University (CSU) in the US, has still not been able to decipher if SARS-CoV-2 could be transmitted by blood transfusion. However, it is an interesting development to watch for. The device used is the Mirasol Pathogen Reduction Technology System which has been developed by us.

Visit link:
Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. - ETHealthworld.com

The latest on the coronavirus outbreak for June 5 – CBC.ca

Unmasking the stealth virus behind COVID-19

Scientists have discovered the pandemic-causing coronavirus is unique in short-circuiting the safest way our immune system kills off a virus which could have implications for using interferon to treat COVID-19, writes CBC's Amina Zafar. Interferon describes a family of proteins produced by the body's immune system in response to an invading viral infection. As the name implies, interferon interferes with the virus's ability to copy itself. Interferon drugs are made in the lab and were used for years to treat hepatitis, a liver infection, as well as other diseases that involve the immune system, such as multiple sclerosis and some cancers.

In May, researchers in Hong Kong published the results of their Phase 2 trial on fewer than 150 people who were admitted to hospital with mild or moderate COVID-19. Participants were randomly assigned to a combination of potential antivirals, including interferon, or placebo injections for two weeks. The findings lent support to the idea of continuing research efforts, including in Canada, to investigate interferon in larger, blinded trials designed to find more definitive answers. Dr. Jordan Feld, a liver specialist at Toronto General Hospital and senior scientist at U of T, previously used interferon to treat people infected with hepatitis. He's now leading a Phase 2 clinical trial to test a targeted form of the drug, called peginterferon lambda, in injections compared with saline placebo injections. "It's kind of like a stealth virus," Feld said of SARS-CoV-2, the virus that causes COVID-19.

Normally, when interferon in the body's white blood cells responds to a viral invader, the interferon sends out a flare signal so nearby cells will work to stop the virus from copying itself or replicating if they, too, should be invaded. In ferrets infected in the lab (a common animal model for studying respiratory viruses), healthy human lung cells and in people with COVID-19, doctors and scientists say it seems like the natural interferon "flies under the radar" of the immune system and isn't activated the way it should be. Feld said the idea behind giving interferon medications is to provide the body with what it should be making to fend off the infection.

The potential therapeutic approach gained scientific backing last month when a study published in the journal Cell showed a "striking" feature of SARS-CoV-2 infection. Ben tenOever is a Canadian-born professor of microbiology at the Icahn School of Medicine at Mount Sinai in New York who led the Cell study and has been flooded with email requests from researchers the world over to test experimental drug compounds against the virus. He said every cell that gets infected has two major jobs:

Most viruses block both of those roles, and what makes SARS-Cov-2 unique is it blocks the call-to-arms function from interferon only. "Treatment with interferon or drugs that induce interferon, the main character in the call to arms, is probably beneficial," tenOever said. "The secret is to do it early," he said, when people have a mild cough and test positive for the virus and haven't developed respiratory distress.

But there could also be mild side-effects. When we're fighting off a flu virus, blame interferon for feeling so crummy, feverish and achy as your immune system kicks into high gear. Likewise, interferon drugs could also lead to flu-like symptoms for a day or two. Individuals enrolling in COVID-19 clinical trials of interferon will need to weigh whether that (potential) shortfall is worth the (potential) payoff of protection from the deadly damage and delivers key answers that only their participation can offer. Matthew Miller, an associate professor of infectious disease and immunology at McMaster University who isn't involved in the clinical trials or studies, called tenOever's paper "an important first step in understanding how our body is responding to this particular new virus."

Click below to watch more from The National

Ontario considering Stage 2 of reopening despite steady stream of new COVID-19 cases

Ontario Premier Doug Ford signalled that he could announce the next phase of loosening Ontario's pandemic restrictions as early as next week, despite a recent uptick in new cases of COVID-19. Stage 2 would allow a wider number of office-based businesses to reopen and expand the maximum size of social gatherings that's currently limited to five. The province's top criteria for further easing its semi-lockdown is a consistent decline over a two- to four-week period in the daily number of new cases.

That benchmark has not declined consistently in the three weeks since May 14, when Ford announced Ontario's first stage of looser restrictions, including allowing non-essential retail stores outside of shopping malls to open for customers. Since that date, Ontario's daily number of reported new cases dipped below 300 only twice; the daily average in that period has been 371, while the average number of new cases daily has trended upward for the past week. By contrast, Quebec's daily number of new cases has steadily declined since early May and has been below 300 for each of the past four days, while British Columbia has not reported more than 30 cases in a single day since May 6. Fifteen of Ontario's 34 public health units have five or fewer active confirmed cases, according to the provincial COVID-19 database on Thursday. None of the public health units north of the Muskoka region has more than three active cases.

Ontario Health Minister Christine Elliott sounded less bullish than the premier about the prospect of a move to loosen restrictions. Elliott said Thursday that the daily count of new cases has "gone back and forth" in the past week to 10 days. "The numbers are gradually going down. We're going to need to see that to continue," she said. There were some positive trends in Ontario's data reported by the provincial Health Ministry including a steady decline in hospitalizations and a decreasing number of long-term care homes with outbreaks but the province's top public health officials have indicated that it's essential they see a steady reduction in the number of new cases daily before recommending a move to Stage 2. A look at the case numbers by their "episode date" (the estimated date of infection, according to the Public Health Ontario interactive data page) shows no sign of a downward trend through the end of May.

Read more about what's happening in Ontario

Federal government to provide $14B to provinces, territories to 'safely' restart economies

The federal government is providing $14 billion to the provinces and territories to help them "safely and carefully" reopen their economies. Prime Minister Justin Trudeau said the money will help pay for more personal protective equipment (PPE) for front-line health-care workers and businesses, and for child care so that parents can go back to work. "Provinces and territories are facing different realities, so flexibility will be important, but here's the bottom line: For seniors and people who need extra support, for kids and workers this plan is here for you," Trudeau said.

Some of the money going to provinces and territories is meant to help them improve the state of long-term care, and to help municipalities continue providing core public services such as transit. The government is saying little at this point about how the money will be carved up and when it will flow. Ontario Premier Doug Ford said it's a "start" but $14 billion falls far short of what's required to address the "massive need" in Canada's most populous province. "The reality is, we have a $23-billion problem in Ontario, and $14 billion for all of Canada ... just won't cut it," he said. Deputy Prime Minister Chrystia Freeland said the government is taking a collaborative approach to fine-tuning the proposal, and stressed that the federal funds are meant to help with the first six to eight months of economic recovery.

Trudeau also announced that Canadians with disabilities will receive a one-time payment of up to $600 to help offset the higher costs of living during the pandemic. The government has announced emergency aid for unemployed Canadians, students, businesses and seniors, but advocates say that people with disabilities were falling through the cracks. Many face increases in the cost of living, such as higher grocery bills and delivery service fees. Conservative MP Dan Albas, his party's critic for employment, workforce development and disability inclusion, said the federal assistance programs announced to date have come with few details and delays in implementation.

Read more about the support for provinces and territories

Canada added 290,000 jobs in May, but unemployment rate inches up to record high

After losing more than three million jobs in March and April, Canada's economy added 290,000 jobs in May, Statistics Canada reported Friday. The data agency reported that 290,000 more people had paid employment in May than in April. The surge means May was the best one-month gain for jobs in Canada in 45 years, although it happened from an admittedly low bar. It also means the economy has now replaced about 10 per cent of the jobs it lost to COVID-19.

The job gains came as a pleasant surprise to economists, most of whom were expecting more job losses for the month. "We are just beginning to dig out of a massively deep hole, and this will take an extended period of time before the rest of the three million job losses can be recouped," Bank of Montreal's Doug Porter said. Despite the gains, Canada's official unemployment rate rose to 13.7 per cent, as 491,000 more people were looking for work in the job market notably students, whose search for summer work isn't normally recorded in the months before May. Porter noted that at 13.7 per cent, Canada's jobless rate is at its highest point since the Second World War. And "that leaves Canada with the dubious distinction of having the highest unemployment rate among all major economies," he said.

The numbers also showed that two-thirds of the new jobs went to men, while women are still bearing the brunt of the impact from COVID-19. That's partly because men are overrepresented in industries like manufacturing and construction, which are recovering faster than other parts of the economy. "As more COVID-19 restrictions are eased in the coming months, labour market outcomes of men and women with children will continue to be monitored," Statistics Canada said. Hassan Yussuff, president of the Canadian Labour Congress, said the data reveals that "women, low-paid workers and racialized workers continue to struggle disproportionately." "Today's numbers also underscore the desperate need for accelerated action on child care to strengthen the job and economic recovery for women," he said.

Read more about Canada's economic situation

Experts say reaching emissions goals and reopening economies amid pandemic shouldn't be mutually exclusive

A recent study published in Nature Climate Change suggests that as a result of global shutdowns because of the COVID-19 pandemic, CO2 emissions in 2020 could drop by roughly seven per cent. The United Nations Environment Program's report from last November found that in order to limit global warming to 1.5 C above pre-industrial levels, CO2 emissions would need to drop by 7.6 per cent annually over the next decade.

At first glance, it might appear as though a devastating economic shutdown is the only way to reach emissions targets set by the UN. But some experts say this isn't the case, and insist there is a way to have economic growth and reduce emissions that adhere to the UN guidelines. "We can't have this [kind of a shutdown] for tackling climate change absolutely not," said Corinne Le Qur, a Canadian professor of climate change science at the University of East Anglia and lead author of the Nature study. "This is a really painful way to get a decrease in emissions." She also noted that it likely won't last, but said this could be an opportunity to funnel money into green technologies as many governments around the world are trying to stimulate their economies during the pandemic.

Don Drummond, an economist who worked for the federal Department of Finance for 23 years, pointed out that emissions in Canada have almost flat-lined, on average, over the past few years during a period of economic growth (prior to the coronavirus pandemic). This, he said, is evidence that reducing emissions to UN guidelines is possible. "We've achieved higher growth with flattening emissions and we can and should go further and achieve positive growth with declining emissions," said Drummond, an adjunct professor at Queen's University and former chief economist at the Toronto-Dominion Bank. Drummond, who was one of the architects of the goods and services tax in 1991, said there is a long history in Canada of scare-mongering that a given new policy will kill the economy, from the GST to the North American Free Trade Agreement. Quite often, it doesn't, he said.

Donation bins begin to reopen in Nova Scotia with easing of COVID-19 restrictions

Donation bins for some organizations in Nova Scotia, including the IWK Foundation and Big Brothers Big Sisters, are reopening as some restrictions around COVID-19 are being lifted in the province https://www.cbc.ca/news/canada/nova-scotia/n-s-reports-no-new-covid-19-cases-1.5600049. "We're doing a very slow return to service," said Shelda Cochrane, a manager with Big Brothers Big Sisters of Greater Halifax. "We just opened up our bins last weekend and we're really just starting to get that message out to the public."

Big Brothers Big Sisters has taken the tape off bins and put up some new signs asking people to take precautions when they place items in the bins. Donated items are sold to Value Village. "We know people have been spring cleaning and holding on to things and they're anxious to get rid of them. But we also want people to be careful when donating," The donations make up about one-third of its annual budget, after expenses, Cochrane said.

The IWK Foundation, seeking used clothing and footwear, reopened its bins this week. The foundation has 600 bins in Nova Scotia and New Brunswick. A third-party organization based in Digby County, N.S., collects items from the bins and resells them. A portion of the proceeds from the bins benefits the IWK Foundation each year, and the donation bin funds will still go toward the cost of programs, new equipment and research at the children's hospital.

Read the full story about the donation bins

Send us your questions

Still looking for more information on the outbreak? Read more about COVID-19's impact on life in Canada, or reach out to us at covid@cbc.ca.

If you have symptoms of the illness caused by the coronavirus, here's what to do in your part of the country.

For full coverage of how your province or territory is responding to COVID-19, visit your local CBC News site.

To get this newsletter daily as an email,subscribe here.

Click below to watch CBC News Network live

More here:
The latest on the coronavirus outbreak for June 5 - CBC.ca

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma – Yahoo Finance

Call Will Feature Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University)

SAN DIEGO, May 28, 2020 /PRNewswire/ --Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M. Eastern Time.

The call will feature presentations by Key Opinion Leaders Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University), who will discuss the current treatment landscape and unmet medical need in EBV-associated lymphoma. The call will be followed by a question and answer session with Drs. Levy and Porcu. Dial-in and webcast information for the call is shown below.

Dial-in and Webcast Information

Domestic:

1-877-705-6003

International:

1-201-493-6725

Conference ID:

13704262

Webcast:

Click Here For Webcast

On the call, Viracta's management team will also provide an update on the clinical development of the company's lead program, nanatinostat in combination with the antiviral valganciclovir as an oral combination therapy in a Phase 2 clinical trial for the treatment of EBV-associated lymphoma.

About the KOLs

Dr. Ronald Levy is a Professor of Medicine and former Chief of the Division of Oncology at Stanford University School of Medicine. Dr. Levy is widely known as a pioneer in the use of monoclonal antibodies for the treatment of cancer. His research efforts have focused on the treatment of lymphoma and he played a key role in developing Rituximab, a drug that has revolutionized lymphoma treatment world-wide. Among many other honors, Dr. Levy was a recipient of the King Faisal International Prize in Medicine.Dr. Levy's current research concentrates on the development of therapeutic vaccine approaches for the treatment of lymphoma and other cancers.

Dr. Pierluigi Porcu is a Professor of Medical Oncology and Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation in the Department of Medical Oncology at Thomas Jefferson University, and a member of the Sidney Kimmel Cancer Center (SKCC).Dr. Porcu's Lab at the SKCC is focused on studying the role of the EBV in a subset of T-cell and NK-cell lymphomas, epigenetic mechanisms of T-cell and NK-cell transformation, new targets of therapy in EBV-associated T-cell and NK-cell lymphomas, and predictive biomarkers of response to epigenetic therapy in lymphoma. For the past 10 years, Dr. Porcu has been listed among the U.S. News & World Report's Top Cancer Doctors in America, Newsweek's Top Hematology Doctors, and since moving to Philadelphia he has been on Philadelphia Magazine's Top Doctors list.

About Nanatinostat

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta.Nanatinostat is selective for specific isoforms of Class 1 HDACs which is key to inducing latent viral genes in EBV-associated malignancies. The nanatinostat and valganciclovir combination is being investigated in EBV-associated lymphomas in an ongoing Phase 2 clinical trial [NCT03397706].

Viracta has received Fast Track designation from the FDA for the nanatinostat and valganciclovir combination in relapsed/refractory lymphomas, as well as Orphan Drug Designation for the treatment of post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T-cell lymphoma.

About EBV-Associated Cancers

Approximately 95% of the world's adult population is infected with Epstein-Barr virus (EBV). Infections are commonly asymptomatic. Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient's life. Under certain circumstances, such cells may undergo malignant transformation and become lymphoma. In addition to lymphomas, EBV is associated with a variety of solid tumors, including nasopharyngeal carcinoma and gastric cancer.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas. Viracta is pursuing application of this Kick and Kill platform approach in other EBV associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other viral related cancers.

Story continues

See more here:
Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma - Yahoo Finance

As Japan reopens, coronavirus testing slowed by bureaucracy and staff shortages – KDAL News

Wednesday, May 27, 2020 8:34 p.m. CDT by Thomson Reuters

By Ju-min Park and Kiyoshi Takenaka

TOKYO (Reuters) - At the beginning of April, a young Japanese sumo wrestler known as Shobushi came down with a fever. His coaches tried calling a local public health centre to get him a coronavirus test, but the phone lines were busy.

For four days, he was turned away by clinics in Tokyo overwhelmed during a surge of COVID-19 cases. He was finally admitted to hospital on April 8 when he began coughing up blood, but died of the disease on May 13, the Japan Sumo Association said.

Shobushi's death caused a public outcry over Japan's testing limitations and reliance on overstretched public health centres at a time when most experts say widespread virus checks are crucial to contain the pandemic.

With Japan lifting its state of emergency and reopening its economy this week, its pandemic response has been hailed as an unlikely success. In a global death toll of more than 300,000, Japan has confirmed around 800 deaths from 16,000 cases.

Yet at the same time, Japan ranks the second lowest in its testing among OECD countries.

As of May 20, Japan conducted 3.4 tests per 1,000 people, far below Italy's 52.5 and 39 in the United States, according to Oxford University data. South Korea has carried out tests on 15 people per 1,000 people.

In more than a dozen interviews with Reuters, public health officials, doctors and experts warned Japan's slow scaling up of tests could mask the scale of infections and make its population vulnerable to future outbreaks.

Critics say vested interests and bureaucracy inside Japan's health ministry caused bottlenecks at overworked public health centres, and officials waited too long to allow private labs to run tests.

"It is true that announced figures for infection and deaths are low, but those are based on the tests that were curbed," said Yasuharu Tokuda, the director of the Muribushi Okinawa Center for Teaching Hospitals. "It is clear that there are quite a few (cases) that have fallen through the cracks."

Even the government's top advisor, Shigeru Omi, told parliament "nobody knows" whether the true number of coronavirus cases "could be 10 times, 12 times or 20 times more than reported."

Omi's panel of experts has called on the government to speed up testing, including of people with mild symptoms.

The health ministry said it is ramping up the use of private labs to reduce the workload on public health centres.

"Our stance that tests should be conducted on people in need has been consistent from the beginning. We have had testing capacity increased continuously," Takuma Kato, a senior health ministry official, told Reuters.

"NOT ENOUGH" TESTS

Public health centres are at the forefront of Japan's response to the pandemic. While South Korea bolstered its public health system in the wake of past epidemics, Japan has halved the number of public health centres since the 1990s.

Struggling with overworked staff and flooded with calls, public health centres have asked the government to allow more private clinics to administer polymerase chain reaction (PCR) tests.

Japan says it can run up to 22,000 PCR tests a day, but less than a third - around 6,000 tests - are actually conducted on a daily basis. About 75% of tests have been processed through public health centres and government institutions, according to the health ministry.

In a previously unreported May 6 letter, the association of public health centre directors urged Katsunobu Kato, the minister of health, to overhaul Japan's testing policy.

"Currently, there are not enough PCR tests conducted for the coronavirus," they wrote in the letter seen by Reuters.

Some regional governments have begun running temporary testing stations with the help of local medical associations in April, bypassing public centres.

IDLE LABS, UNUSED MACHINES

While public health centres are overwhelmed, university labs are sitting idle.

Shinya Yamanaka, a Nobel Prize-winning stem cell biologist at Kyoto University, has offered his lab to boost testing capacity.

"If we can make good use of resources at places like university labs, PCR testing can exceed 100,000 (per day), far more than 20,000," Yamanaka said in an internet TV debate with Prime Minister Shinzo Abe on May 6.

The health ministry welcomed his proposal, but said further considerations were needed.

"We are grateful for their offer of help at this time of emergency. We want to work together, carefully matching our needs to their offer," Masami Sakoi, the assistant health minister, told Reuters.

Critics say testing was limited, in part, by health ministry technocrats who wanted to maintain a tight grip on information, rather than cooperate with private institutions.

Kenji Shibuya, who heads the Institute for Population Health at King's College London, said officials wanted to gather high-quality research data using public health centres.

The health ministry denies suggestions that ministry technocrats are intentionally curbing testing, and say their approach has proven successful so far.

Sakoi from the health ministry said it was important to carry out PCR tests that doctors deemed necessary, and pointed out Japan's public insurance system started covering the tests in March as part of the government's effort to make them more accessible.

"When we think about using the test results to form policy measures, the current method needs to be maintained for the time being though concerns that it lacks flexibility for boosting the number of tests is understandable," Sakoi said.

Still, the approach is alarming some experts.

"It's safer to assume that Japan has just been lucky than to believe it has taken the right steps," said Tokuda, the epidemiology expert.

(Reporting by Ju-min Park, Kiyoshi Takenaka, Antoni Slodkowski, Ami Miyazaki, Sakura Murakami; Editing by Mari Saito and Lincoln Feast.)

Follow this link:
As Japan reopens, coronavirus testing slowed by bureaucracy and staff shortages - KDAL News